United StatesNovo Nordisk has halted two cardiovascular trials of its drug ziltivekimab, which aims to lower inflammation to improve heart health. The decision came after a data monitoring committee determined the trials were unlikely to show positive results. This follows the drug’s earlier failure in the ZEUS trial, where it reduced inflammation markers but did not lower the risk of major cardiac events like heart attacks or death. The trials, named HERMES and ATHENA, were paused after the company informed investigators on Friday. The setbacks mark another challenge for the approach of using anti-inflammatory drugs to treat cardiovascular disease.
Bias read (Center): The article presents factual information about pharmaceutical trials without overt ideological framing. It reports on the outcomes of clinical trials and their implications for medical treatment without taking a clear partisan stance. The focus remains on scientific and medical developments rather
Why factuality (95): The article accurately reports that Novo Nordisk has stopped two trials (HERMES and ATHENA) of ziltivekimab due to a data monitoring committee finding them unlikely to succeed. It also references the prior failure of the ZEUS trial, aligning with the cross-source consensus on the drug’s lack of succ
Why objectivity (92): The article presents the information in a neutral tone, avoiding overt bias or emotional language. While it mentions 'another blow for the approach,' this is a factual statement rather than an opinion. The overall reporting remains balanced.
